Response rates to checkpoint inhibition were generally more favorable in individuals with increased PD-1 or PD-L1 expression, but upregulation was not a requisite for success and was not seen to correlate with response in MCC. This evidence concerns the gene CD274 and Merkel cell skin cancer.